Evolve

Protecting Pyrazinamide and Fluoroquinolones for successful multi-drug resistant tuberculosis (MDR-TB) treatment

Objective

The objective of the study is to assess the frequency of additional drug resistance under sub-optimal treatment for drug-resistant tuberculosis.


Description

Most patients diagnosed with drug-resistant TB started their therapy before a full drug susceptibility testing (DST) profile is available. A proportion of these patients may initially receive a suboptimal prescription which may be revised once the full DST is known. This entails both inappropriate drugs, and/or inappropriate drug dosage. This study will monitor the effects of such inappropriate therapy on the development of additional drug resistance that will jeopardize successful treatment.

For this we will study a cohort of patients with drug resistant TB from Moldova and Belarus, countries with a high frequency of drug resistance in TB patients.

We will compare the drug resistance profiles of patients who will start directly on appropriate therapy with those who start with inappropriate therapy. Results will be directly relevant for future treatment and monitoring guidelines.


AIGHD Research Lead

Assoc. Prof. Frank van Leth


Partners

RIVM

University Hospital Groningen

The Republic Scientific and Practical Center of Pulmonology and Tuberculosis  Dolginovski, Belarus

Institute of Phthisiopneumology of Ministry of Health, Labour and Social Protection of the Republic of Moldova, Moldova


Contact info

Richard Anthony (richard.anthony@rivm.nl)


Funders

ZONMw


Countries

Netherlands

Moldova

Belarus